RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Robert Bitterman and Keith Brownlie have been appointed to the Company’s Board of Directors. Mr. Bitterman and Mr. Brownlie both bring extensive industry experience that will be instrumental to supporting RXi’s growth and development initiatives.
Mr. Bitterman brings over 18 years of leadership experience in the pharmaceutical and biologic life science industry to RXi. Mr. Bitterman currently serves as the President & CEO of Cutanea Life Sciences, Inc., a wholly owned subsidiary of Maruho Company, LTD, a specialty pharma company focused on diseased and aging skin. Prior to Cutanea, he served as President and CEO for Isolagen, Inc., an international public, bioscience technology company whose primary proprietary platform used human fibroblasts for soft tissue enhancement. For 10 years, Mr. Bitterman served as the President and GM of Aventis' Dermik Laboratories, a global strategic business unit focused on therapeutic and aesthetic dermatology development and commercialization. “We are honored to have Robert join our Board of Directors,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that “His broad experience in the field of dermatology will be a valuable resource to RXi as we progress our first candidate into the clinic.”
Mr. Brownlie comes to RXi after a distinguished career with Ernst & Young that spanned 36 years. During his tenure, he rapidly became one of the leading accounting specialists for life sciences companies of the greater New York area. For the last 20 years at Ernst & Young, he has held the position of Metro New York Area Life Sciences Industry Leader. Mr. Brownlie has extensive experience with SEC registration statements, initial public offerings and recurrent reporting. In his accounting career he has been involved in over 100 public offerings. Until 2010, when he retired from Ernst & Young, he was a member of Ernst & Young’s National Life Sciences Committee, and he is a member of the American Institute of CPAs. Mr. Brownlie is currently a member of the Board of Directors of Epicept and Soligenix, where in both companies he also is chairman of the Audit Committee. “It is privilege for us at RXi to have someone of the caliber of Keith join RXi’s Board of Directors,” said Dr. Cauwenbergh. He added that “Keith joins us at a time that we expect to see RXi transform form a pure research platform company into a biotechnology product development company. His expertise will be beneficial in supporting and expediting this transition.”